Kathryn Cowie

Kathryn Cowie

Auto-generated profile, based on publicly available information

Kathryn Cowie

Nested Knowledge Saint Paul, MN United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in JMIR Medical Informatics
Verified
Journal Article
Open access
KCKathryn Cowie
Kathryn Cowie
ARAsad Rahmatullah
Asad Rahmatullah
Nicole Janell HardyNicole Janell Hardy
Nicole Janell Hardy
KHKarl Holub
Karl Holub
KKKevin Kallmes
Kevin Kallmes
Background: Systematic reviews (SRs) are central to evaluating therapies but have high costs in terms of both time and money. Many software tools exist to assist with SRs, but most tools do not support the full process, and transparency and replicability of SR depend on performing and presenting evidence according to established best practices. Objective: This study aims to provide a basis for comparing and selecting between web-based software tools that support SR, by conducting a feature-by-feature comparison of SR tools. Methods: We searched for SR tools by reviewing any such tool listed in the SR Toolbox, previous reviews of SR tools, and qualitative Google searching. We included all SR tools that were currently functional and required no coding, and excluded reference managers, desktop applications, and statistical software. The list of features to assess was populated by combining all features assessed in 4 previous reviews of SR tools; we also added 5 features (manual addition, screening automation, dual extraction, living review, and public outputs) that were independently noted as best practices or enhancements of transparency and replicability. Then, 2 reviewers assigned binary present or absent assessments to all SR tools with respect to all features, and a third reviewer adjudicated all disagreements. Results: Of the 53 SR tools found, 55% (29/53) were excluded, leaving 45% (24/53) for assessment. In total, 30 features were assessed across 6 classes, and the interobserver agreement was 86.46%. Giotto Compliance (27/30, 90%), DistillerSR (26/30, 87%), and Nested Knowledge (26/30, 87%) support the most features, followed by EPPI-Reviewer Web (25/30, 83%), LitStream (23/30, 77%), JBI SUMARI (21/30, 70%), and SRDB.PRO (VTS Software) (21/30, 70%). Fewer than half of all the features assessed are supported by 7 tools: RobotAnalyst (National Centre for Text Mining), SRDR (Agency for Healthcare Research and Quality), SyRF (Systematic Review Facility), Data Abstraction Assistant (Center for Evidence Synthesis in Health), SR Accelerator (Institute for Evidence-Based Healthcare), RobotReviewer (RobotReviewer), and COVID-NMA (COVID-NMA). Notably, of the 24 tools, only 10 (42%) support direct search, only 7 (29%) offer dual extraction, and only 13 (54%) offer living/updatable reviews. Conclusions: DistillerSR, Nested Knowledge, and EPPI-Reviewer Web each offer a high density of SR-focused web-based tools. By transparent comparison and discussion regarding SR tool functionality, the medical community can both choose among existing software offerings and note the areas of growth needed, most notably in the support of living reviews.

5 May 2021 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
Adam DmytriwAdam Dmytriw
Adam Dmytriw
RCRicha Chibbar
Richa Chibbar
PCPetty Pin Yu Chen
Petty Pin Yu Chen
MTMichael D. Traynor
Michael D. Traynor
DKDong Wook Kim
Dong Wook Kim
PKPraneeth Reddy Keesari
Praneeth Reddy Keesari
Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) often leads to mortality. Outcomes of patients with COVID-19-related ARDS compared to ARDS unrelated to COVID-1...

23 November 2022 in JMIR Medical Informatics
Verified
Journal Article
Open access
KCKathryn Cowie
Kathryn Cowie
ARAsad Rahmatullah
Asad Rahmatullah
Nicole Janell HardyNicole Janell Hardy
Nicole Janell Hardy
KHKarl Holub
Karl Holub
KKKevin Kallmes
Kevin Kallmes
[This corrects the article DOI: 10.2196/33219.].

28 August 2021 in JMIR Preprints
Verified
Preprint
Open access
KCKathryn Cowie
Kathryn Cowie
ARAsad Rahmatullah
Asad Rahmatullah
Nicole Janell HardyNicole Janell Hardy
Nicole Janell Hardy
KHKarl Holub
Karl Holub
KKKevin Kallmes
Kevin Kallmes
BACKGROUND Systematic reviews (SRs) are central to evaluating therapies but have high costs in terms of both time and money. Many software tools exist to assist with SRs, but most tools do not support the full process, and transparency and replicability of SR depend on performing and presenting evidence according to established best practices. OBJECTIVE This study aims to provide a basis for comparing and selecting between web-based software tools that support SR, by conducting a feature-by-feature comparison of SR tools. METHODS We searched for SR tools by reviewing any such tool listed in the SR Toolbox, previous reviews of SR tools, and qualitative Google searching. We included all SR tools that were currently functional and required no coding, and excluded reference managers, desktop applications, and statistical software. The list of features to assess was populated by combining all features assessed in 4 previous reviews of SR tools; we also added 5 features (manual addition, screening automation, dual extraction, living review, and public outputs) that were independently noted as best practices or enhancements of transparency and replicability. Then, 2 reviewers assigned binary present or absent assessments to all SR tools with respect to all features, and a third reviewer adjudicated all disagreements. RESULTS Of the 53 SR tools found, 55% (29/53) were excluded, leaving 45% (24/53) for assessment. In total, 30 features were assessed across 6 classes, and the interobserver agreement was 86.46%. DistillerSR (Evidence Partners; 26/30, 87%), Nested Knowledge (Nested Knowledge; 25/30, 83%), and EPPI-Reviewer Web (EPPI-Centre; 24/30, 80%) support the most features followed by Giotto Compliance (Giotto Compliance; 23/30, 77%), LitStream (ICF), and SRDB.PRO (VTS Software). Fewer than half of all the features assessed are supported by 7 tools: RobotAnalyst (National Centre for Text Mining), SRDR (Agency for Healthcare Research and Quality), SyRF (Systematic Review Facility), Data Abstraction Assistant (Center for Evidence Synthesis in Health), SR Accelerator (Institute for Evidence-Based Healthcare), RobotReviewer (RobotReviewer), and COVID-NMA (COVID-NMA). Notably, of the 24 tools, only 10 (42%) support direct search, only 7 (29%) offer dual extraction, and only 13 (54%) offer living/updatable reviews. CONCLUSIONS DistillerSR, Nested Knowledge, and EPPI-Reviewer Web each offer a high density of SR-focused web-based tools. By transparent comparison and discussion regarding SR tool functionality, the medical community can both choose among existing software offerings and note the areas of growth needed, most notably in the support of living reviews.

22 August 2022 in JMIR Preprints
Verified
Preprint
Open access
JPJohn Michael Pederson
John Michael Pederson
KCKathryn Cowie
Kathryn Cowie
ABAveri Barrett
Averi Barrett
LSLauren Siegel
Lauren Siegel
HLHannah Lyons
Hannah Lyons
ADAlan K. Davis
Alan K. Davis
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for MDD. METHODS This study will be performed as a living systematic review housed in the Nested Knowledge online platform, allowing for data extraction, analysis, and synthesis to occur on an ongoing basis as new evidence emerges. The study is registered with PROSPERO (ID: CRD42021290905) and will be compliant with Preferred Reporting Items for Systematic Review and Meta-Analysis of Individual Participant Data (PRISMA-IPD). Major databases (PubMed, Embase, SCOPUS, PyschINFO) and international clinical trials registries will be systematically searched for relevant trials. Randomized and non-randomized trials of psilocybin for the treatment of MDD will be included; authors will be contacted if individual patient data is not readily available. The three populations of interest are patients with MDD, patients with treatment-resistant MDD, and patients with MDD and life-threatening illness. The primary outcome is depression as measured by validated clinical scales (e.g., GRID-Hamilton Depression Rating Scale [GRID-HAMD], Beck Depression Inventory [BDI], Hospital Anxiety and Depression Scale - Depression Subscale [HADS-D]). Heterogeneous scale results will be transformed to z-scores and aggregated to create a composite depression outcome. Secondary outcomes include anxiety, demoralization/hopelessness, quality of life, and death acceptance. We will analyze outcome data using hierarchical mixed-effects regression models. In order to consider clustering effects from study to study, a three-level hierarchical structure will be used: the participants within each trial are considered level one, the study is level two, and the treatment group is level three. Hierarchical regressions are also conducted to examine various effect moderators of treatment outcomes, including patient age, patient sex, baseline score for a given clinical outcome, history of psilocybin use, and psilocybin dose (including the interaction of dose volume and dose schedule). All analyses will be performed on a modified intention-to-treat basis. Repeat literature searches, screening, and subsequent updates to the review will be conducted on an ongoing basis. RESULTS The initial review and subsequent updates will be published in a peer-reviewed journal and made available online via the Nested Knowledge platform. CONCLUSIONS Despite growing interest in psilocybin as a therapy for chronic, severe, or intractable MDD, there are gaps in the literature. A rapidly expanding evidence base requires a living systematic review to adequately inform clinical practice and policymaking around psychedelics for psychological and mood disorders. This meta-analysis seeks to meet that need by providing a transparent, up-to-date, and accessible living review of psilocybin for MDD.